ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	14.04B
Revenue (ttm)	3.19B
Net Income (ttm)	193.01M
Shares Out	790.74M
EPS (ttm)	0.24
PE Ratio	73.90
Forward PE	46.71
Dividend	0.35 (1.98%)
Ex-Dividend Date	Jul 3, 2025

Volume	249,627
Average Volume	497,775
Open	17.70
Previous Close	17.70
Day's Range	17.70 - 17.85
52-Week Range	16.25 - 23.95
Beta	0.29
RSI	53.46
Earnings Date	Nov 5, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.